Dimethyl Sulfoxide
Apexbio Technology LLC Enrofloxacin 93106-60-6 10mM (in 1mL DMSO)
Enrofloxacin a fluoroquinolone antibiotic exerts antibacterial activity by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes essential for DNA replication and transcription This mechanism disrupts the DNA synthesis of pathogenic bacteria resulting in bacteriostatic outcomes In vitro experiments indicate that Enrofloxacin displays antimicrobial activity against Mycoplasma species such as Mycoplasma bovis with a minimum inhibitory concentration (MIC90) around 0 312 g/mL In biomedical research this compound is primarily utilized to establish microbial infection models and to study bacterial resistance mechanisms pharmaceutical efficacy and antibacterial pharmacodynamics
Apexbio Technology LLC GLPG0634 1206161-97-8 10mM (in 1mL DMSO)
GLPG0634 (CAS 1206161-97-8) is a selective small-molecule inhibitor targeting Janus kinase 1 (JAK1) It exhibits potent inhibitory activity against JAK1 and moderate inhibition against JAK2 with reported IC50 values of approximately 10 nM and 28 nM respectively GLPG0634 preferentially interferes with signal transduction pathways mediated by JAK1 affecting cytokine-induced phosphorylation of STAT1 and STAT5 thus attenuating differentiation of Th1 Th2 and to a lesser degree Th17 cells In preclinical rat models of collagen-induced arthritis oral administration reduced inflammatory cell infiltration and bone damage supporting its potential application in inflammatory disease research
Medchemexpress LLC Carbocysteine sulfoxide | 5439-87-2 | MFCD21364079 | 99.0% | 195.19 | C5H9NO5S | 25 MG
Carbocysteine sulfoxide is a small-molecule drug intermediate and a reported impurity of carbocisteine supplied for research and analytical use. It is intended for impurity profiling, method development, and related analytical applications. The compound is identified by CAS number 5439-87-2 and has formula C5H9NO5S and a molecular weight of 195.19 g/mol. Storage and handling recommendations are provided in the product certificate of analysis.
Apexbio Technology LLC CAL-101 (Idelalisib, GS-1101) 870281-82-6 10mM (in 1mL DMSO)
CAL-101 (Idelalisib GS-1101 CAS 870281-82-6) is a selective inhibitor targeting the p110 isoform of phosphatidylinositol 3-kinase (PI3K) an enzyme involved in signaling pathways critical for proliferation and survival of malignant B cells By inhibiting PI3K p110 CAL-101 reduces PI3K-mediated phosphorylation of Akt and other downstream factors leading to enhanced PARP cleavage and caspase activation ultimately inducing apoptosis in malignant B cells CAL-101 has been demonstrated to counteract survival signals initiated by molecules such as CD40 ligand (CD40L) TNF- and fibronectin This agent is valuable in investigating B-cell malignancies
Apexbio Technology LLC MK-5108 (VX-689) 1010085-13-8 10mM (in 1mL DMSO)
MK-5108 (VX-689 CAS 1010085-13-8) is a selective inhibitor targeting Aurora A kinase (AAK) functioning through competitive interaction with its ATP-binding pocket It exhibits sub-nanomolar inhibition of Aurora A kinase (IC50 0 064 nM) and displays additional inhibitory activity against Aurora B and Aurora C kinases (IC50 14 nM and IC50 12 nM respectively) MK-5108 has been extensively studied in cancer research contexts demonstrating antiproliferative activity across various tumor types including breast cervical colorectal ovarian and pancreatic cancers
Apexbio Technology LLC AZD2461 1174043-16-3 10mM (in 1mL DMSO)
AZD2461 (CAS 1174043-16-3) is a novel small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) exhibiting potency with an IC50 of 5 nM PARP enzymes are pivotal regulators of DNA repair and apoptosis-associated processes In breast cancer cell lines such as SKBR-3 and MCF-7 AZD2461 reduces cell viability in a concentration- and time-dependent manner arresting cells predominantly in the G2 phase In BRCA1-deficient mouse KB1P tumors AZD2461 disrupts PARP activity regardless of P-glycoprotein-mediated resistance to other inhibitors like olaparib highlighting its utility in overcoming drug resistance and elucidating DNA repair pathways in cancer research
Apexbio Technology LLC ZM 447439 331771-20-1 10mM (in 1mL DMSO)
ZM 447439 (CAS 331771-20-1) is a selective inhibitor of Aurora kinases a subgroup within the serine/threonine kinase family involved in chromosome segregation during cell division It inhibits recombinant Aurora A and Aurora B kinases with IC50 values of approximately 110 nM and 130 nM respectively consequently reducing phosphorylation of histone H3 at serine 10 ZM 447439 demonstrates limited inhibitory activity towards other kinases with IC50 values above 10 M for CDK1/2/4 IKK1/2 PLK1 CHK1 cFLT2 KDR2 FAK and Zap-70 In biological research ZM 447439 is commonly employed to study mitotic regulation chromosomal alignment and apoptosis signaling pathways
Apexbio Technology LLC Everolimus (RAD001) 159351-69-6 10mM (in 1mL DMSO)
Everolimus (RAD001) is an orally bioavailable small-molecule inhibitor targeting mammalian target of rapamycin (mTOR) an integral serine/threonine kinase regulating cell proliferation metabolism and survival within the PI3K/Akt pathway Everolimus binds intracellularly to the immunophilin FKBP12 the resulting complex subsequently interacts directly with mTOR inhibiting its kinase activity thereby reducing downstream phosphorylation of S6 kinase 1 (S6K1) and the eukaryotic initiation factor 4E-binding protein (4EBP) Functionally Everolimus exerts immunosuppressive properties used clinically to prevent organ transplant rejection and demonstrates antitumor activity against several malignancies including renal cell carcinoma and basal cell carcinoma Commonly utilized in cancer research Everolimus inhibits mTOR with IC50 values reported in the low nanomolar range ( 1 3 nM)
Apexbio Technology LLC SKI II 312636-16-1 10mM (in 1mL DMSO)
SKI II (CAS 312636-16-1) is a small-molecule inhibitor of sphingosine kinase (SK) an enzyme involved in converting sphingosine into sphingosine-1-phosphate (S1P) SKI II inhibits SK activity with an IC50 of 0 5 M through a mechanism independent of competition at the ATP-binding site Selectivity assessments showed no inhibitory effect against human kinases ERK2 PKC-I or PI3K Cellular assays demonstrate that SKI II effectively inhibits endogenous SK reducing S1P synthesis and subsequently suppressing proliferation and inducing apoptosis in various cancer cell lines including MDA-MB-231 T-24 MCF-7 and MCF-7/VP cells
Apexbio Technology LLC YM155 781661-94-7 10mM (in 1mL DMSO)
YM155 (Sepantronium Bromide CAS 781661-94-7) is a small-molecule inhibitor targeting survivin the smallest protein member of the inhibitor of apoptosis (IAP) gene family YM155 potently suppresses survivin expression while demonstrating minimal influence on other IAP family members or BCL-2-associated proteins Preclinical research shows YM155 inhibits proliferation and induces apoptosis across various human cancer cell lines including non-small cell lung cancer (NSCLC) melanoma bladder cancer aggressive non-Hodgkin lymphoma triple-negative breast cancer (TNBC) and Wilms tumor models In animal xenograft studies YM155 administration results in tumor regression reduces spontaneous metastasis and notably prolongs survival
Apexbio Technology LLC Q-VD(OMe)-OPh 10mM (in 1mL DMSO)
Q-VD(OMe)-OPh is a pan-caspase inhibitor structurally identified as quinolyl-valyl-O-methylaspartyl-[2 6-difluorophenoxy]-methyl ketone As a broad-spectrum inhibitor Q-VD(OMe)-OPh reversibly targets multiple caspases involved in apoptotic signaling including initiator caspases (such as caspases 8 9 10 and 12) and executioner caspases (such as caspase 3) thereby blocking intrinsic extrinsic and endoplasmic reticulum-mediated apoptotic pathways In recombinant enzyme assays this inhibitor displays nanomolar-range IC values against caspases 1 3 8 and 9 Due to minimal cytotoxicity at tested concentrations Q-VD(OMe)-OPh serves as a tool compound in apoptosis-related biomedical research applied broadly for dissecting caspase-dependent apoptotic mechanisms and evaluating cytoprotective strategies
Apexbio Technology LLC Temsirolimus 162635-04-3 10mM (in 1mL DMSO)
Temsirolimus (CCI-779) is an ester analog of rapamycin functioning as an inhibitor of the mammalian target of rapamycin (mTOR) The compound suppresses mTOR signaling pathways thus inhibiting cellular proliferation and growth In preclinical studies on breast cancer cell lines Temsirolimus displayed inhibitory activities with reported IC50 values of 0 6 nM in BT-474 cells 0 7 nM in MDA-MB-468 and SKBR-3 cells and 50 nM in MCF-7 cells It has been examined in xenograft models of tumors with PTEN mutations and multiple myeloma for investigating pathways related to cell-cycle progression and proliferation regulated by mTOR
Apexbio Technology LLC PF-562271 HCl 939791-41-0 10mM (in 1mL DMSO)
PF-562271 HCl (CAS 939791-41-0) is a potent ATP-competitive reversible inhibitor targeting focal adhesion kinase (FAK) and its homolog proline-rich tyrosine kinase 2 (Pyk2) It inhibits FAK and Pyk2 enzymatic activity with reported IC50 values of 1 5 nmol/L and 14 nmol/L respectively FAK is a non-receptor tyrosine kinase regulating cell adhesion migration and growth while Pyk2 shares structural similarity to FAK In animal models of cancer PF-562271 reduces tumor progression and metastatic spread with dose-dependent suppression of FAK phosphorylation (EC50 93 ng/mL) Thus PF-562271 serves as an important tool for investigating FAK/Pyk2-mediated pathways in oncology research